{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:17:04Z","timestamp":1788326224972,"version":"build-2803163510"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2026.1975494","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:23:12Z","timestamp":1788322992000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Editorial: Recent advances in theranostics: endocrine tumours and beyond"],"prefix":"10.3389","volume":"13","author":[{"given":"Alberto","family":"Nieri","sequence":"first","affiliation":[{"name":"Nuclear Medicine Unit, Oncological Department, Azienda Ospedaliero Universitaria Senese","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Imperiale","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Nouvel H\u00f4pital Civil, University Hospitals of Strasbourg, University of Strasbourg","place":["Strasbourg, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Urso","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Ferrara","place":["Ferrara, Italy"]},{"name":"Nuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara","place":["Ferrara, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"(177)Lu-dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12020-022-03170-0","article-title":"Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review","volume":"78","author":"Urso","year":"2022","journal-title":"Endocrine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"101802","DOI":"10.1016\/j.adro.2025.101802","article-title":"Efficacy, safety, and patient reported outcomes of rhenium-skin cancer therapy for non-melanoma skin cancer: 1-year results from the EPIC-skin study","volume":"10","author":"Cardaci","year":"2025","journal-title":"Advances in Radiation Oncology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s41181-024-00264-0","article-title":"99mTc-labeled FAPI compounds for cancer and inflammation: from radiochemistry to the first clinical applications","volume":"9","author":"Boschi","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"key":"B7","doi-asserted-by":"publisher","first-page":"00197","DOI":"10.1016\/j.euo.2026.07.007","article-title":"PSMA PET in prostate cancer: clinical value, access challenges, and priorities for implementation","author":"Peyrottes","year":"2026","journal-title":"Eur Urol Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40336-026-00769-5","article-title":"Radioligand therapy and tumor dosimetry: where are we and where are we going; are we in the era of personalized radioligand therapy?","volume":"14","author":"Serani","year":"2026","journal-title":"Clin Transl Imaging"},{"key":"B11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s40336-026-00761-z","article-title":"The future of nuclear medicine in Italy","volume":"14","author":"Alongi","year":"2026","journal-title":"Clin Transl Imaging"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1975494\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:23:12Z","timestamp":1788322992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1975494\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":11,"alternative-id":["10.3389\/fmed.2026.1975494"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1975494","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"article-number":"1975494"}}